Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762475 · ClinicalTrials.gov registry record · Phase 2
Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.
A Phase 2 study, sponsored by Uniformed Services University of the Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01762475 is a Phase 2 study that has completed, run by Uniformed Services University of the Health Sciences. The registered enrollment target is 59 participants.
The verdict
NCT01762475, a Phase 2 study, has completed, sponsored by Uniformed Services University of the Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether sildenafil (Viagra®) is effective in improving cerebral blood flow and cerebrovascular reactivity inpatients who have persistent symptoms at least 6 months after a traumatic brain injury (TBI).
Interventions
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01762475
The ClinicalTrials.gov registry entry for NCT01762475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Uniformed Services University of the Health Sciences, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil is the first listed.
NCT01762475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01762475 about?
NCT01762475 is a clinical study titled "Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.". The purpose of this study is to determine whether sildenafil (Viagra®) is effective in improving cerebral blood flow and cerebrovascular reactivity inpatients who have persistent symptoms at least 6 months after a traumatic brain injury (TBI).
What is the current status of trial NCT01762475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2013-01. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01762475?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT01762475?
This trial is sponsored by Uniformed Services University of the Health Sciences, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.